Trial Profile
A 12-week Efficacy Evaluation of WBI-1001 Cream in Patients With Atopic Dermatitis: A Multi-centered, Double-blinded Study (6-week Placebo-controlled Phase Followed by a 6-week Non-placebo Controlled Phase).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Oct 2014
Price :
$35
*
At a glance
- Drugs Tapinarof (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Welichem Biotech
- 30 Oct 2014 New trial record